Gary Bellinger

3.3k total citations · 2 hit papers
13 papers, 1.9k citations indexed

About

Gary Bellinger is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Gary Bellinger has authored 13 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Gary Bellinger's work include Cancer, Hypoxia, and Metabolism (4 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer-related Molecular Pathways (3 papers). Gary Bellinger is often cited by papers focused on Cancer, Hypoxia, and Metabolism (4 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer-related Molecular Pathways (3 papers). Gary Bellinger collaborates with scholars based in United States, Canada and Switzerland. Gary Bellinger's co-authors include Lewis C. Cantley, John M. Asara, George Poulogiannis, Atsuo T. Sasaki, Min Shen, Craig J. Thomas, Douglas S. Auld, Matthew G. Vander Heiden, Matthew B. Boxer and Jian‐kang Jiang and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Gary Bellinger

13 papers receiving 1.9k citations

Hit Papers

Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Speci... 2011 2026 2016 2021 2011 2013 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses
    2011 941 citations Dimitrios Anastasiou, George Poulogiannis et al. Science profile →
  2. AMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1
    2013 517 citations Ning Wu, Bin Zheng et al. Molecular Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary Bellinger United States 11 1.4k 749 360 208 201 13 1.9k
Evan C. Lien United States 17 1.4k 0.9× 777 1.0× 393 1.1× 178 0.9× 161 0.8× 28 2.0k
Dimitrios Anastasiou United Kingdom 15 1.7k 1.2× 981 1.3× 384 1.1× 254 1.2× 173 0.9× 30 2.5k
Zhimin Lu United States 12 1.8k 1.2× 734 1.0× 394 1.1× 126 0.6× 314 1.6× 13 2.3k
Taro Hitosugi United States 21 1.6k 1.1× 1.1k 1.4× 269 0.7× 148 0.7× 158 0.8× 34 2.1k
Prashanth T. Bhaskar United States 9 1.9k 1.3× 890 1.2× 335 0.9× 203 1.0× 186 0.9× 9 2.5k
Hyonchol Jang South Korea 25 1.5k 1.0× 520 0.7× 245 0.7× 123 0.6× 138 0.7× 66 1.9k
David Barneda United Kingdom 13 1.0k 0.7× 648 0.9× 413 1.1× 279 1.3× 168 0.8× 17 1.6k
Brooke M. Emerling United States 20 1.4k 1.0× 559 0.7× 248 0.7× 332 1.6× 257 1.3× 36 2.1k
Michalis Agathocleous United States 11 1.2k 0.8× 599 0.8× 243 0.7× 142 0.7× 106 0.5× 19 2.0k
Kristin K. Nelson United States 16 1.4k 1.0× 647 0.9× 220 0.6× 151 0.7× 103 0.5× 16 2.1k

Countries citing papers authored by Gary Bellinger

Since Specialization
Citations

This map shows the geographic impact of Gary Bellinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Bellinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Bellinger more than expected).

Fields of papers citing papers by Gary Bellinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Bellinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Bellinger. The network helps show where Gary Bellinger may publish in the future.

Co-authorship network of co-authors of Gary Bellinger

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Bellinger. A scholar is included among the top collaborators of Gary Bellinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Bellinger. Gary Bellinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Biktasova, Asel, Michael Hajek, Andrew K. Sewell, et al.. (2017). Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer. Clinical Cancer Research. 23(23). 7276–7287. 46 indexed citations
2.
Biktasova, Asel, Michael Hajek, Gary Bellinger, et al.. (2017). Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner. Oncogenesis. 6(4). e314–e314. 12 indexed citations
3.
Juvekar, Ashish, Hai Hu, Sina Yadegarynia, et al.. (2016). Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. Proceedings of the National Academy of Sciences. 113(30). E4338–47. 71 indexed citations
4.
Hajek, Michael, et al.. (2016). Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget. 7(25). 38598–38611. 14 indexed citations
5.
Fendt, Sarah‐Maria, Eric L. Bell, Mark A. Keibler, et al.. (2013). Metformin Decreases Glucose Oxidation and Increases the Dependency of Prostate Cancer Cells on Reductive Glutamine Metabolism. Cancer Research. 73(14). 4429–4438. 7 indexed citations
6.
Emerling, Brooke M., Jonathan Hurov, George Poulogiannis, et al.. (2013). Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors. Cell. 155(4). 844–857. 144 indexed citations
7.
Emerling, Brooke M., Cyril H. Benes, George Poulogiannis, et al.. (2013). Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proceedings of the National Academy of Sciences. 110(9). 3483–3488. 49 indexed citations
8.
Wu, Ning, Bin Zheng, Adam J. Shaywitz, et al.. (2013). AMPK-Dependent Degradation of TXNIP upon Energy Stress Leads to Enhanced Glucose Uptake via GLUT1. Molecular Cell. 49(6). 1167–1175. 517 indexed citations breakdown →
9.
Heiden, Matthew G. Vander, Dimitrios Anastasiou, George Poulogiannis, et al.. (2011). Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses. DSpace@MIT (Massachusetts Institute of Technology). 2 indexed citations
10.
Anastasiou, Dimitrios, George Poulogiannis, John M. Asara, et al.. (2011). Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses. Science. 334(6060). 1278–1283. 941 indexed citations breakdown →
11.
Jackson-Fisher, Amy, Gary Bellinger, Jerrica L. Breindel, et al.. (2008). ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Research. 10(6). R96–R96. 44 indexed citations
12.
Jackson-Fisher, Amy, Gary Bellinger, Elaine Shum, et al.. (2006). Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. Oncogene. 25(41). 5664–5672. 19 indexed citations
13.
Jackson-Fisher, Amy, Gary Bellinger, Rajani Ramabhadran, et al.. (2004). ErbB2 is required for ductal morphogenesis of the mammary gland. Proceedings of the National Academy of Sciences. 101(49). 17138–17143. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Evan C. Lien Breakdown of academic impact, for papers by Dimitrios Anastasiou Breakdown of academic impact, for papers by Zhimin Lu Breakdown of academic impact, for papers by Taro Hitosugi Breakdown of academic impact, for papers by Prashanth T. Bhaskar Breakdown of academic impact, for papers by Hyonchol Jang Breakdown of academic impact, for papers by David Barneda Breakdown of academic impact, for papers by Brooke M. Emerling Breakdown of academic impact, for papers by Michalis Agathocleous Breakdown of academic impact, for papers by Kristin K. Nelson
Rankless by CCL
2026